BridgeBio Oncology Therapeutics (BBOT) Accounts Payables (2024 - 2026)

BridgeBio Oncology Therapeutics has reported Accounts Payables for 3 years, with the latest figure at $12.1 million in Q1 2026.

• Quarterly Accounts Payables changed N/A year-over-year to $12.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.1 million (changed N/A YoY) and the FY2025 annual result came in at $1.4 million, down 55.3% from the prior year.
• Accounts Payables grew to $12.1 million in Q1 2026 per BBOT's latest filing, from $1.4 million in the prior quarter.
• Over five years, Accounts Payables peaked at $12.1 million in Q1 2026 and troughed at $9687.0 in Q1 2024.
• A 3-year average of $3.8 million and a median of $2.8 million in 2024 frame the typical range for Accounts Payables.
• The widest YoY moves for Accounts Payables: up 55.3% in 2025, down 55.3% in 2025.
• Over 3 years, Accounts Payables stood at $3.1 million in 2024, then slumped by 55.3% to $1.4 million in 2025, then soared by 779.91% to $12.1 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $12.1 million, $1.4 million, and $3.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.